GlassScriptPhysician profile
John P Cardin
NPI 1467411744
$787.60
in general payments reported to CMS, 2019-2025
15 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.84 · 2020: $54.85 · 2021: $32.28 · 2022: $61.97 · 2023: $82.42 · 2024: $228 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $147.81 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.08 | 2019-2024 | |
| Shield Therapeutics INC | $84.80 | 2024 | |
| Hologic Sales and Service, LLC | $78.95 | 2020-2024 | Aptima, Thinprep 2000 Processor |
| Sage Therapeutics, LLC | $76.92 | 2023-2024 | |
| Lilly USA, LLC | $58.19 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Myriad Women'S Health, INC. | $49.64 | 2023 | |
| Abbott Laboratories | $46.05 | 2024-2025 | Freestyle Libre 3, Eterna |
| Evofem Biosciences, INC. | $20.61 | 2022 | |
| Organon LLC | $20.49 | 2025 | Nexplanon |
| Roche Diagnostics Corporation | $19.95 | 2019 | |
| Amag Pharmaceuticals, INC. | $19.75 | 2019 | |
| Phadia US INC. | $19.28 | 2025 | Immunocap |
| Dexcom, INC. | $17.25 | 2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $14.83 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cardin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.